Discharge Summary

Name: Johanna Eyler (June 28, 1965) **Patient ID**: SYN140

Date of Diagnosis: March 3, 2022
Primary Diagnosis: NSCLC, Adenocarcinoma, Stage IV with liver metastases
Molecular profile: MET exon 14 skipping mutation
PD-L1 Status: TPS 25%, CPS 30, IC 1+
First-Line Treatment: Tepotinib 500 mg PO daily
Start Date: March 25, 2022
Current Status: 2L Crizotinib

---

1. Diagnostic Workup and Genomics

Patient presented with right upper quadrant pain and jaundice. Labs revealed elevated LFTs, with imaging showing a 4.6 cm left lower lobe mass and multiple hypodense liver lesions. Biopsy of a hepatic lesion confirmed adenocarcinoma of lung origin.

NGS (FoundationOne) identified a MET exon 14 skipping mutation. PD-L1 expression was intermediate (TPS 25%). Given her MET-driven disease, she was started on tepotinib.

---

2. Clinical Course and Toxicities

The patient achieved a deep partial response at 12 weeks with >60% shrinkage of both lung and hepatic disease. Tolerability was fair, with some complications:

- Grade 2 peripheral edema (managed with furosemide PRN)
- Intermittent elevated LFTs (max ALT 145 U/L, returned to baseline)
- Mild nausea, resolved with ondansetron

At 15 months, surveillance CT revealed new left hepatic lesions, biopsy-confirmed progression.

---

3. Second-Line and Surveillance

She was transitioned to **crizotinib** in July 2023. Although not formally approved for MET14, retrospective case reports and registry trials support its off-label utility. She remains clinically well, with stable disease as of last imaging (March 2025).

Lab March 2025:

- ALT/AST: 32/28 U/L
- CA 19-9: Normal
- CEA: Stable at 3.8 ng/mL

- MET RNA expression: Persistently high
- No resistance mutations detected on ctDNA

---

4. Comorbidities

- GERD
- Depression (on duloxetine)
- Hypokalemia (chronic, on supplementation)
- Iron-deficiency anemia (oral iron)

---

5. Current Plan

• Continue crizotinib pending ongoing benefit
• ctDNA every 3 months
• Imaging Q8-10 weeks
• Monitor for visual disturbances, QT prolongation
• Consider clinical trial if progression occurs (e.g., savolitinib or antibody-MET conjugates)

Signed,
Dr. Rami Hassan, MD
Thoracic Oncology
April 14, 2025